AP NEWS

Global Hereditary Angioedema Therapeutics Market 2018-2022 - Innovative Treatment Strategies / Improved Route of Administration Products / Development of Monoclonal Antibody - ResearchAndMarkets.com

September 25, 2018

DUBLIN--(BUSINESS WIRE)--Sep 25, 2018--The “Global Hereditary Angioedema Therapeutics Market 2018-2022” report has been added to ResearchAndMarkets.com’s offering.

The Global Hereditary Angioedema Therapeutics Market to grow at a CAGR of 8.94% during the period 2018-2022.

The report covers the present scenario and the growth prospects of the hereditary angioedema therapeutics market. To calculate the market size, the report considers the revenue generated from the hereditary angioedema therapeutics. The report also includes a discussion of the key vendors operating in this market.

According to the report, one driver influencing this market is the increasing prevalence of hereditary angioedema. The rising cases of hereditary angioedema are increasing the possibility of transmission of the disease in the future generation. Therefore, it is expected that the distribution of the disease and the demand for the therapeutics will increase during the coming years, which in turn, results in the growth of the global hereditary angioedema therapeutics market.

Development of monoclonal antibody is one of the major trends in the market. The development of therapeutics for the treatment of disease requires various approvals and experimentation. Shire after conducting clinical trials for the treatment of hereditary angioedema, launched the first monoclonal antibody, Lanadelumab (SHP643)

Further, the report states that one challenge affecting this market is the high cost of treatment. Although the medications for HAE is covered under patient healthcare schemes in most countries, the indirect costs associated with the treatment makes the treatment quite expensive for the patients, leading to less patient adherence.

Key vendors

BioCryst Pharmaceuticals Cipla CSL Pharming Group Shire

Key Topics Covered:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

PART 05: MARKET SIZING 2017-2022

PART 06: FIVE FORCES ANALYSIS

PART 07: PIPELINE LANDSCAPE

PART 08: MARKET SEGMENTATION BY PRODUCT

Segmentation by product Comparison by product C1 inhibitors Icatibant Ecallantide Others - Market size and forecast 2017-2022 Market opportunity by product

PART 09: CUSTOMER LANDSCAPE

PART 10: REGIONAL LANDSCAPE

Geographical segmentation Regional comparison Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

PART 13: MARKET TRENDS

Innovative treatment strategies Improved route of administration products Development of monoclonal antibody

PART 14: VENDOR LANDSCAPE

Landscape disruption

PART 15: VENDOR ANALYSIS

Vendors covered Vendor classification Market positioning of vendors

For more information about this report visit https://www.researchandmarkets.com/research/bt2tqt/global_hereditary?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180925005798/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Immune Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/25/2018 10:40 AM/DISC: 09/25/2018 10:40 AM

http://www.businesswire.com/news/home/20180925005798/en

AP RADIO
Update hourly